Reactions 1704, p302 - 2 Jun 2018 Lichenoid graft versus host disease: case report A woman in her 30s developed lichenoid graft versus host disease (GVHD) while receiving treatment with pembrolizumab [age at the time of reaction onset and route not stated clearly] The woman, at the age of 32 years, was diagnosed with Hodgkin’s lymphoma in 2013. She underwent autologous stem cell transplant. However, eight months later, relapse occurred. Subsequently, she was treated with fludarabine, cyclophosphamide and mesna [uromitexan]. She also underwent haploidentical allergeneic haematopoietic cell transplantation. Post-transplant, she developed lichenoid cutaneous GVHD. Consequently, she was treated with unspecified corticosteroids. However, one year later, lichenoid GVHD relapsed. Consequently, she was treated with brentuximab vedotin [brentuximab]. Subsequently, her lichenoid GVHD resolved. Subsequently, she was treated with one infusion of low dose pembrolizumab 50mg for underlying lymphoma. However, within one week, she developed severe cutaneous and oral lichenoid GVHD. Therefore, she was treated with prednisone, triamcinolone and narrow band UVB. Six weeks after the pembrolizumab dose, the cutaneous eruption still persisted. Author comment: "This case reminds us that anti-PD1 may be a doubleedged sword; the enhanced T cell-mediated graft versus tumour effect can intensify the [graft versus host disease]." Chan L, et al. PD-1 inhibitor, a double-edged sword? Lichenoid graft versus host disease triggered by pembrolizumab in a patient with Hodgkin’s lymphoma. Australasian Journal of Dermatology 59 (Suppl. 1): 45, May 2018. Available from: URL: http://doi.org/10.1111/ajd.17_12815 [abstract] - Australia 803323601 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera